Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Gynecologic Tumors

NCT05468307 is registered in ClinicalTrials.gov with Shanghai Juncell Therapeutics as lead sponsor.

NCT NCT05468307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05468307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Gynecologic Tumors
Lead sponsor
Shanghai Juncell Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 10, 2022
Completion date
December 30, 2024
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gynecologic tumors, effects of immunotherapy, til engineered with membrane-binding cytokine, treatment side effects